- 专利标题： TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
-
申请号： EP21160203.2申请日： 2015-04-07
-
公开(公告)号： EP3888674A1公开(公告)日： 2021-10-06
- 发明人: BYRD, John , DUBOVSKY, Jason , FRAIETTA, Joseph , GILL, Saar , GLASS, David , JOHNSON, Amy , JUNE, Carl H. , KENDERIAN, Saad , MANNICK, Joan , MAUS, Marcela , MURPHY, Leon , MUTHUSAMY, Natarajan , PORTER, David L. , RUELLA, Marco , SELLERS, William Raj , WASIK, Mariusz , BROGDON, Jennifer
- 申请人： Novartis AG , The Trustees of The University of Pennsylvania
- 申请人地址： CH 4056 Basel Lichtstrasse 35; US Philadelphia, PA 19104 3160 Chestnut Street Suite 200
- 代理机构： Mathys & Squire
- 优先权： US201462097278 P 20141229
- 主分类号： A61K39/00
- IPC分类号： A61K39/00 ; A61K35/17 ; A61K31/436 ; A61P35/02
摘要：
The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
公开/授权文献
信息查询
